These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22176465)

  • 41. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux oesophagitis. Solo Investigator Group.
    Bate CM; Booth SN; Crowe JP; Mountford RA; Keeling PW; Hepworth-Jones B; Taylor MD; Richardson PD
    Gut; 1995 Apr; 36(4):492-8. PubMed ID: 7737552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prolonged remission of oesophagitis does not alter the magnitude of oesophageal acid exposure.
    Singh P; Taylor RH; Colin-Jones DG
    Scand J Gastroenterol; 1994 Jan; 29(1):11-6. PubMed ID: 8128170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Omeprazole: therapy of choice in intellectually disabled children.
    Böhmer CJ; Niezen-de Boer RC; Klinkenberg-Knol EC; Meuwissen SG
    Arch Pediatr Adolesc Med; 1998 Nov; 152(11):1113-8. PubMed ID: 9811290
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Causal diagrams, gastroesophageal reflux and erosive oesophagitis.
    Shahar E
    J Eval Clin Pract; 2013 Oct; 19(5):976-83. PubMed ID: 22804828
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term treatment of erosive esophagitis with omeprazole: does it work?
    Rabeneck L
    Gastroenterology; 1995 Feb; 108(2):613-4. PubMed ID: 7835610
    [No Abstract]   [Full Text] [Related]  

  • 46. Safety and efficacy of long term esomeprazole therapy in patients with healed erosive oesophagitis.
    Maton PN; Vakil NB; Levine JG; Hwang C; Skammer W; Lundborg P;
    Drug Saf; 2001; 24(8):625-35. PubMed ID: 11480494
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Histological esophagitis: clinical and histological response to omeprazole in children.
    Strauss RS; Calenda KA; Dayal Y; Mobassaleh M
    Dig Dis Sci; 1999 Jan; 44(1):134-9. PubMed ID: 9952234
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Choice of long-term strategy for the management of patients with severe esophagitis: a cost-utility analysis.
    Heudebert GR; Marks R; Wilcox CM; Centor RM
    Gastroenterology; 1997 Apr; 112(4):1078-86. PubMed ID: 9097989
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High-dose omeprazole in esophagitis with stenosis after surgical treatment of esophageal atresia.
    Van Biervliet S; Van Winckel M; Robberecht E; Kerremans I
    J Pediatr Surg; 2001 Sep; 36(9):1416-8. PubMed ID: 11528618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Is omeprazole helpful in the management of children with reflux oesophagitis?
    Varughese LA; Mazur LJ
    Arch Dis Child; 2002 Jul; 87(1):78-80. PubMed ID: 12089134
    [No Abstract]   [Full Text] [Related]  

  • 51. Relapse rate of patients after healing of oesophagitis--a prospective study of alginate as self-care treatment for 6 months. French Co-operative Study Group.
    Poynard T
    Aliment Pharmacol Ther; 1993 Aug; 7(4):385-92. PubMed ID: 8218752
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Economic evaluation of long-term management strategies for erosive oesophagitis.
    Goeree R; O'Brien B; Hunt R; Blackhouse G; Willan A; Watson J
    Pharmacoeconomics; 1999 Dec; 16(6):679-97. PubMed ID: 10724795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-Term Clinical Course after Successful Initial Treatment in Patients with Mild Erosive Esophagitis: A Prospective Follow-Up Study.
    Okanobu H; Kohno T; Boda K; Ochi H; Furukawa Y
    Digestion; 2023; 104(4):283-290. PubMed ID: 36716726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.
    Creutzfeldt W
    Drug Saf; 1994 Jan; 10(1):66-82. PubMed ID: 8136088
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Predictive factors for healing of esophagitis. Prospective study during ranitidine therapy].
    Fournet J; Ottignon Y; Alberola B
    Presse Med; 1993 Jun; 22(23):1087-90. PubMed ID: 8415460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics of intravenous omeprazole in children.
    Jacqz-Aigrain E; Bellaich M; Faure C; Andre J; Rohrlich P; Baudouin V; Navarro J
    Eur J Clin Pharmacol; 1994; 47(2):181-5. PubMed ID: 7859807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment approaches to reflux oesophagitis.
    Lieberman D
    Drugs; 1990 May; 39(5):674-80. PubMed ID: 2191848
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ranitidine therapy for esophagitis in children with developmental disabilities.
    Kaufman SS; Loseke CA; Young RJ; Perry DA
    Clin Pediatr (Phila); 1996 Sep; 35(9):451-6. PubMed ID: 8877242
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials.
    Sharma N; Donnellan C; Preston C; Delaney B; Duckett G; Moayyedi P
    Gut; 2004 May; 53 Suppl 4(Suppl 4):iv58-65. PubMed ID: 15082617
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.